Press Releases

Date Title
1/3/23 Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/28/22 Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
11/23/22 Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
11/2/22 Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
10/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/26/22 Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico
10/26/22 Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey
10/26/22 Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
Displaying 31 - 40 of 788